Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
10/2002
10/22/2002US6468488 Mg-Al anionic clay having 3R2 stacking
10/22/2002CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/17/2002WO2002081636A2 Protein modification and maintenance molecules
10/17/2002WO2002081606A1 Cupua seed-origin fat, process for producing the same and use thereof
10/17/2002WO2002081521A2 Osteoprotegerin in milk
10/17/2002WO2002081508A2 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002WO2002081499A2 Somatostatin agonists
10/17/2002WO2002081494A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002WO2002081475A1 Jun kinase inhibitors
10/17/2002WO2002081463A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002WO2002081460A1 Lipid lowering biphenylcarboxamides
10/17/2002WO2002081457A1 `1,4!-diazepane-1-carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists
10/17/2002WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002WO2002081430A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002WO2002081428A1 Benzene compound and salt thereof
10/17/2002WO2002081420A1 Cyclooctanone derivative and cyclodecanone derivative, and use thereof
10/17/2002WO2002080982A2 Nucleic acid mucosal immunization
10/17/2002WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002WO2002080973A1 Composition for use in therapy of hard tissue of mammal and method of therapy thereof
10/17/2002WO2002080958A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/17/2002WO2002080956A2 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c
10/17/2002WO2002080955A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002WO2002080947A1 Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same
10/17/2002WO2002080946A1 Compositions for preventing and/or treating oral diseases
10/17/2002WO2002080941A1 Compositions for preparing external carbon dioxide agents
10/17/2002WO2002080939A2 Ionene polymers and their use as antimicrobial agents
10/17/2002WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002WO2002080931A1 New use of glyconjugates of glucocorticosteroids as a targeting to the colon
10/17/2002WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002WO2002080904A1 Liver funcion protecting or ameliorating agent
10/17/2002WO2002080899A1 Remedial agent for digestive disease
10/17/2002WO2002080898A2 Methods for treating hyperactive gastric motility
10/17/2002WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002WO2002080887A2 Timed pulse release composition
10/17/2002WO2002080852A2 Genes expressed in intestinal epithelium and peyer's patch m cells
10/17/2002WO2002080754A2 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002WO2002080676A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002WO2002059114A9 Lfa-1 antagonist compounds
10/17/2002WO2002057261A3 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
10/17/2002WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002WO2002029061A3 G-protein coupled receptors
10/17/2002WO2002021932A3 Animal feed, feed additive and therapeutic agent against intestinal inflammation
10/17/2002WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002WO2002010192A9 Somatostatin analogues
10/17/2002WO2002007772A3 Improved oral dosage formulations
10/17/2002WO2002002133A3 Peptide composition for treatment of periodontal diseases and prevention of skin aging
10/17/2002WO2001098354A3 Human receptors
10/17/2002WO2001098344A3 Angiogenesis-modulating compositions and uses
10/17/2002WO2001098323A3 G-protein coupled receptors
10/17/2002WO2001070664A3 Lipoxin analogs and methods for the treatment of periodontal disease
10/17/2002WO2001058922A9 Method and compositions for treating hepatocellular cancer
10/17/2002WO2001058241A9 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
10/17/2002WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002US20020151695 Transforming growth factor-beta-related molecules and uses thereof
10/17/2002US20020151596 Novel process to prepare 2-aminoindan derivatives
10/17/2002US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002US20020151557 CRF receptor antagonists and methods relating thereto
10/17/2002US20020151554 Cyclin-dependent kinase inhibitors such as (4-Amino-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-thiazolyl) (2,3-dihydro-1,4-benzodioxin-6-yl)methanone for treatment of breast, lung, colon, and prostate cancer/tumors
10/17/2002US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002US20020151514 Genes associated with mechanical stress, expression products therefrom, and uses thereof
10/17/2002US20020151505 Treatment of helicobacter with isothiocyanates
10/17/2002US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002US20020151472 Trefoil factor (TFF) peptides (tricyclic peptides, e.g., TFF2 peptides), for increasing the viscosity of mucus layers; used for treating damaged or abnormal mucus layers, e.g. in the gastrointestinal tract, respiratory/urogential systems, eyes
10/17/2002US20020151015 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/17/2002US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002US20020150977 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases
10/17/2002US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002US20020150544 Water soluble film for oral administration with instant wettability
10/17/2002DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002CA2443334A1 Protein modification and maintenance molecules
10/17/2002CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002CA2443085A1 Somatostatin agonists
10/17/2002CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002CA2442382A1 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002CA2441538A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002CA2439503A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/17/2002CA2434693A1 Ionene polymers and their use as antimicrobial agents
10/16/2002EP1249241A1 Adsorbent for oral administration
10/16/2002EP1249238A2 Topical pharmaceutical composition comprising betanechol
10/16/2002EP1249235A1 Remedies for hepatitis containing alanine and glycine
10/16/2002EP1248847A1 Irak-4: compositions and methods of use
10/16/2002EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002EP1248801A1 Human polynucleotides, polypeptides, and antibodies
1 ... 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 ... 1258